EUVIMEDEUVIMED entdecken
LeserbriefKlinische Studie (Phase II)Open Access · CC BY 4.0

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial

Xiaohui Suo, Zheng Fang, Dongmei Wang, Liyun Zhao, Jie Liu, Hong Li, Xiaojun Ma, Congcong Zhang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao und 12 weitere

Hematological Oncology · 2024

DOI: 10.1002/hon.3296 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Hematological Oncology, 2024. Verfasst von Xiaohui Suo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Handan Central Hospital, Handan, Hebei, China. Hauptthemen laut MEDLINE: Daunorubicin, Cytarabine, Leukemia, Myeloid, Acute, Sulfonamides. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special project for research and development ability of colleges and universities, National Natural Science Foundation of China, Tianjin Key Medical Discipline Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DaunorubicinCytarabineLeukemia, Myeloid, AcuteSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicHumansMaleFemaleMiddle AgedAgedAdult

Substanzen

venetoclaxDaunorubicinCytarabineSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, Handan Central Hospital, Handan, Hebei, China.
  • Department of Hematology, The Second People's Hospital of Guiyang, Guiyang, Guizhou, China.
  • Department of Hematology, Harrison International Peace Hospital, Hengshui, Hebei, China.
  • Department of Hematology, People Hospital of XingTai, Xing Tai, Hebei, China.
  • Department of Hematology, Sinopharm Tongmei General Hospital, Datong, Shanxi, China.
  • Department of Hematology, Daqing Oilfied General Hospital, Daqing, Heilongjiang, China.

ORCID-Profile: Linyu Yuan, Kaiqi Liu

Förderung

  • Special project for research and development ability of colleges and universities
  • National Natural Science Foundation of China
  • Tianjin Key Medical Discipline Construction Project
  • Shandong Society of Geriatrics 2021 Annual science and technology Development Plan project

Zitieren

APA

Suo, X., Fang, Z., Wang, D., Zhao, L., Liu, J., Li, H., Ma, X., Zhang, C., Zhao, X., Shi, R., Wu, Y., Jiao, Z., Song, J., Zhang, L., Li, L., Zhang, S., Lu, X., Yuan, L., Gao, S., …, & Mi, Y. (2024). Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. Hematological Oncology. https://doi.org/10.1002/hon.3296

Vancouver

Suo X, Fang Z, Wang D, Zhao L, Liu J, Li H, et al. Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. Hematological Oncology. 2024. doi:10.1002/hon.3296

BibTeX
@article{Suo2024,
  author = {Suo, Xiaohui and Fang, Zheng and Wang, Dongmei and Zhao, Liyun and Liu, Jie and Li, Hong and Ma, Xiaojun and Zhang, Congcong and Zhao, Xuemei and Shi, Rui and Wu, Yan and Jiao, Zongjiu and Song, Jiaojie and Zhang, Ling and Li, Ling and Zhang, Suping and Lu, Xinxiao and Yuan, Linyu and Gao, Sifeng and Zhang, Jilei and Liu, Kaiqi and Zhao, Xingli and Bai, Guanchen and Mi, Yingchang},
  title = {Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3296}
}
Kostenlos starten →